Received: 27 October 2020
Accepted: 17 January 2021
First Online: 29 January 2021
Ethics approval and consent to participate
: Institutional Review Board approval of the study protocol was obtained prior to study conduct and included a waiver of informed consent. The Yale Human Investigation Committee determined that this study did not involve human subjects.
: Not applicable
: L.P. has received consulting fees and honoraria from Seattle Genetics, Pfizer, Astra Zeneca, Merck, Novartis, Bristol Myers Squibb, Pfizer, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, and Daiichi and institutional research funding from Seattle Genetics, AstraZeneca, Merck, Pfizer, and Bristol Myers Squibb. K.A. has received research funding from Genentech and consulting fees/honoria from Genentech, Huron pharmaceuticals, and Celgene and equity from Carrum health. S.M. has received consulting fees from Eisai, Celgene, and Cardinal Health and grant funding from Genentech and Pfizer. M.R. has grant funding from the ASCO Conquer Cancer YIA grant.